{"id":795724,"date":"2026-10-08T08:12:14","date_gmt":"2026-10-08T08:12:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/795724\/"},"modified":"2026-10-08T08:12:14","modified_gmt":"2026-10-08T08:12:14","slug":"the-scariest-thing-about-gray-market-peptides-is-how-little-we-know","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/795724\/","title":{"rendered":"The scariest thing about gray-market peptides is how little we know"},"content":{"rendered":"

This is Optimizer<\/a>, a weekly newsletter sent from Verge senior reviewer Victoria Song<\/a> that dissects and discusses the latest gizmos and potions that swear they\u2019re going to change your life. Opt in for Optimizer here<\/a>.<\/p>\n

Finding concrete data about gray-market peptides is a Sisyphean task. Unlike bona fide clinical drug trials, there are no official numbers. There\u2019s little to no safety data. Some peptides have more anecdotal evidence than others, but a stranger on r\/peptides is, perhaps, not an ideal information source. The fact is most people partaking in a dubiously legal activity aren\u2019t going to shout it from the rooftops. What we do know about many of these unregulated, unapproved substances is simply this: A lot of people are taking them, unsupervised by medical professionals.<\/p>\n

Take BPC-157 \u2014 one half of the infamous \u201cWolverine\u201d stack<\/a>. The BPC in BPC-157 stands for \u201cbody protection compound.\u201d The substance was originally found in gastric juice in 1993 and is thought to promote injury recovery. It supposedly works by creating new blood vessels, promoting cell growth, and repairing damaged tissues like tendons, muscles, and ligaments. You know, Wolverine-y stuff. Sounds great. Except it\u2019s not approved by any regulatory body, has primarily been studied in animals, and has limited clinical evidence in humans. One systematic review from 2025<\/a> found only 35 preclinical studies and a single clinical study for BPC-157 in humans.<\/p>\n

Nevertheless, BPC-157 is on a lot of people\u2019s minds. That same systematic review states that, in 2024, there were over 50 million views for BPC-157 videos on YouTube and TikTok. According to Google Trends, there\u2019s been a 1,600 percent increase in traditional web searches for BPC-157 in the United States in the last five years. That jumps to over 5,000 percent for YouTube searches. As for real-life usage data \u2014 it\u2019s impossible to find reliable numbers.<\/p>\n

That said, a recent preprint study<\/a> attempted to capture how real-world BPC-157 use has increased. The study, yet to go through peer review, is a retrospective look at anonymized electronic health records using a large language model to detect mentions of the peptide in clinical notes. This itself is an imperfect method, as BPC-157 has no insurance code or a uniform way for medical providers to indicate a patient is using it. Even so, the preprint highlights interesting \u2014 and concerning \u2014 trends.<\/p>\n

\u201c[BPC-157 usage] was kind of benign during the pandemic and the deep end of the pandemic, but it\u2019s skyrocketed over the last few quarters. Over the last three years, the use has increased significantly,\u201d says Venky Soundararajan, one of the study\u2019s authors and chief scientific officer of nference, an AI startup that uses LLMs to find insights from clinical records.<\/p>\n

Put plainly, the study found roughly 54 confirmed patients using BPC-157 in Q1 2022. (The real number is likely much higher, but this is a snapshot based on the records the researchers had access to.) That number jumped to 1,018 in Q1 2026. According to Soundararajan, about 33 percent of patients who used BPC-157 didn\u2019t pursue any other therapies or drug use. Roughly half, however, stacked it with other substances. (Chief among those were testosterone, non-steroidal anti-inflammatory drugs, and TB-500, the other half of the Wolverine stack, which also supports tissue repair.) He also noted that the majority of patients were taking BPC-157 orally, followed by injections.<\/p>\n

\"There\u2019s<\/a><\/p>\n

There\u2019s a marked increased in BPC-157 usage. Screenshot: nference<\/p>\n

\u201cThe average BPC-157 user who\u2019s showing up to the doctor is getting younger and younger \u2014 they\u2019re in the upper 40s as an average age and is very likely a Caucasian white patient,\u201d says Soundararajan. \u201cAnd from the time the product is [first] used and the time they show up to discuss their use with a doctor, at least two months has elapsed.\u201d As for the type of doctors, BPC-157 is most commonly reported to family practice and internal medicine, followed by gastroenterologists and orthopedic surgeons.<\/p>\n

Even so, this data has flaws, acknowledges Soundararajan. For example, he pointed out that 96 percent of patients who disclosed their usage were Caucasian, compared to the 2 percent that were African American. That\u2019s a dramatic gap from what the researchers would\u2019ve expected statistically based on the source data, which was 78 percent Caucasian and 17 percent African American. This doesn\u2019t mean African Americans aren\u2019t taking BPC-157 \u2014 they may simply feel less confident talking about it with doctors compared to Caucasians. As for why someone might feel that way, I\u2019ve conducted interviews with peptide users who say they don\u2019t want judgment, don\u2019t trust their doctor is knowledgeable about the subject, or fear it may lead to repercussions with insurance.<\/p>\n

Another problem, Soundararajan says, is that this preprint can\u2019t really give reliable insights as to BPC-157\u2019s efficacy in humans or safety. Only a small subset reported adverse reactions \u2014 roughly 2 to 3 percent. However, the problem is that data is anecdotal. In a clinical setting, he explains, researchers and doctors evaluate adverse reactions on a graded scale. Minor, manageable adverse effects might get reported in records, but severe cases requiring hospitalizations may not. Pain, he says, is also not an objective assessment. In the study, most of the positive effects of BPC-157 were self-reported by patients. However, physicians rarely intervened to say they also saw an improvement in the patient\u2019s condition. Also, 66 percent of the cases showed no documented response on whether BPC-157 worked or not \u2014 only that the patient had tried it.<\/p>\n

\u201cThe medical record has a bias. Obviously, there are those who are using the product for performance enhancement who are not talking about it,\u201d says Soundararajan. For example, the top recorded reason for BPC-157 use is pain management. On the one hand, that indicates BPC-157 users may be turning to the substance because there\u2019s an unmet need that legal therapies can\u2019t address. But, he says, those are self-selecting patients. It\u2019s possible that only patients with positive experiences were likely to talk about their usage in an official setting.<\/p>\n

Pro-peptide users might say this is evidence that BPC-157 works. Some might even conclude from this preprint that, given their individual circumstances, the risk calculus is worth a go. But from a regulatory standpoint, this simply isn\u2019t good enough.<\/p>\n

\"Again,<\/a><\/p>\n

Again, this shows part of a picture, but not the whole. Screenshot: nference<\/p>\n

Perhaps the scariest thing is that even Soundararajan can\u2019t say whether the preprint truly says anything about BPC-157. The patients in the preprint obtained the peptide from gray-market sources, so it\u2019s possible that some were taking another substance entirely. There\u2019s always the chance that the positive effects recorded are simply the placebo effect. We\u2019ll never know.<\/p>\n

But this is the sort of information physicians, researchers, journalists, regulators, and the peptide-curious have to go off of. A fuzzy picture that tells part of a story, but not the entirety. Imperfect data like this is better than nothing, but it raises more questions than it half-answers.<\/p>\n

The only thing that anyone can truly conclude from a study like this? We don\u2019t know enough, but BPC-157 isn\u2019t going away anytime soon. Doctors will have to start thinking about how to talk to patients who do turn to the gray market.<\/p>\n

\u201cThe reason we are handicapped, not only us but others when they try to replicate these studies, is that they\u2019ll be relying on clinical notes alone,\u201d says Soundararajan. \u201cYou need to make it easy for the healthcare provider to structure the conversations that they\u2019re having with patients for unapproved products. This is one thing where we think regulation should change. We believe health record manufacturers need to make it easy for doctors to record. Who\u2019s the source? Where did you get the product from?\u201d<\/p>\n

Even if that helps paint a clearer picture of gray-market use, that, too, is a stopgap solution. One thing that everyone can agree on is that both prospective studies and gold-standard clinical trials are necessary. It\u2019s \u201cjust\u201d a matter of who will pony up the millions required. And it\u2019s not isolated to BPC-157. This goes for all the commonly used gray-market peptides.<\/p>\n

Until then, incomplete data is all we have.<\/p>\n

Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.Victoria SongClose\"Victoria<\/p>\n

Victoria Song<\/p>\n

Senior Reviewer, Wearable Tech<\/p>\n

Posts from this author will be added to your daily email digest and your homepage feed.<\/p>\n

FollowFollow<\/p>\n

See All by Victoria Song<\/a><\/p>\n

ColumnClose<\/p>\n

Column<\/p>\n

Posts from this topic will be added to your daily email digest and your homepage feed.<\/p>\n

FollowFollow<\/p>\n

See All Column<\/a><\/p>\n

HealthClose<\/p>\n

Health<\/p>\n

Posts from this topic will be added to your daily email digest and your homepage feed.<\/p>\n

FollowFollow<\/p>\n

See All Health<\/a><\/p>\n

OptimizerClose<\/p>\n

Optimizer<\/p>\n

Posts from this topic will be added to your daily email digest and your homepage feed.<\/p>\n

FollowFollow<\/p>\n

See All Optimizer<\/a><\/p>\n

ScienceClose<\/p>\n

Science<\/p>\n

Posts from this topic will be added to your daily email digest and your homepage feed.<\/p>\n

FollowFollow<\/p>\n

See All Science<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"This is Optimizer, a weekly newsletter sent from Verge senior reviewer Victoria Song that dissects and discusses the…\n","protected":false},"author":2,"featured_media":795725,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[22162,102,6591,73849,90,56,54,55],"class_list":["post-795724","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-column","tag-health","tag-medication","tag-optimizer","tag-science","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/795724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=795724"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/795724\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/795725"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=795724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=795724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=795724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}